Cargando…
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
BACKGROUND: A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well studied. METHODS: We carried out a population-based case–control study in the Lombardy...
Autores principales: | Mancia, Giuseppe, Rea, Federico, Ludergnani, Monica, Apolone, Giovanni, Corrao, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206933/ https://www.ncbi.nlm.nih.gov/pubmed/32356627 http://dx.doi.org/10.1056/NEJMoa2006923 |
Ejemplares similares
-
The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020) -
Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022) -
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
por: Reynolds, Harmony R., et al.
Publicado: (2020) -
Risk of Covid-19 with renin-angiotensin-aldosterone system medications
Publicado: (2020) -
Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19
por: Sarzani, Riccardo, et al.
Publicado: (2020)